ClinicalTrials.gg
CompletedNCT04313608Updated Mar 25, 2024Results posted

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

A Phase 1 interventional study of Glofitamab and Gemcitabine in B-cell Lymphoma, sponsored by Hoffmann-La Roche. Completed at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing glofitamab in Lymphoma, B-Cell — 9 open to participants now, 11 under way, 1 of them phase 3. glofitamab · Lymphoma, B-Cell.

Enrollment
12th of 13
23 · median 45
Started
2020
with 1 other
Phase 1
2 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
2 of 13
Hoffmann-La Roche

Among the 13 studies testing glofitamab in Lymphoma, B-Cell, this one is the 12th largest by enrollment, is one of 2 that started in 2020, is one of 2 in phase 1, and was the 2nd registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

9 of the 13 studies testing glofitamab in Lymphoma, B-Cell are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About glofitamab

glofitamab: first FDA approval 2023 (COLUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing glofitamab in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety and efficacy of glofitamab or mosunetuzumab in combination with gemcitabine and oxaliplatin (Glofit-GemOx or Mosun-GemOx) in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL).

03

Conditions studied

  • B-cell Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0,1, or 2
  • confirmed B-cell lymphoma, including one of the following diagnoses per the 2016 World Health Organization (WHO) classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS); HGBCL with MYC and BCL2 and/or BCL6 rearrangements; HGBCL, NOS
  • R/R disease, defined as follows: Relapse: disease that has recurred following a response that lasted >/=6 months after completion of last ; : disease that progressed during therapy or progressed within 6 months (\<6 months) of prior therapy
  • At least one line of prior systemic therapy
  • At least one bi-dimensionally measurable nodal lesion or one bi-dimensionally measurable extranodal lesion, as measured on positron emission tomography-computed tomography (PET/CT) scan
  • Adequate hematologic function
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods, and agreement to refrain from donating eggs, as follows: Women must remain abstinent or use contraceptive methods with a failure rate of \<1% per year during the treatment period and for at least 18 months after the final dose of obinutuzumab, 6 months after the final dose of gemcitabine, 9 months after the final dose of oxaliplatin, 3 months after the final dose of mosunetuzumab, 3 months after the final dose of tocilizumab, and 2 months after the final dose of glofitamab. Women must refrain from donating eggs during this same period
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm, as follows: With a female partner of childbearing potential or pregnant female partners, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \<1% per year during the treatment period and for at least 2 months after the final dose of glofitamab, 2 months after the final dose of mosunetuzumab, 2 months after the final dose of tocilizumab (if applicable), 3 months after the final dose of obinutuzumab, and 6 months after the final dose of oxaliplatin or gemcitabine to avoid exposing the embryo. Men must refrain from donating sperm during this same period.

Exclusion criteria

Exclusion Criteria

  • Participant has failed only one and is a candidate for stem cell transplantation
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
  • to obinutuzumab, gemcitabine, oxaliplatin, or tocilizumab
  • Prior treatment with a bispecific antibody targeting both CD20 and CD3, including glofitamab and mosunetuzumab
  • Grade >1 peripheral neuropathy
  • Treatment with radiotherapy, chemotherapy, immunotherapy, therapy, or any agent for the purposes of treating cancer within 2 weeks prior to first study treatment
  • Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to the first study treatment
  • Primary or secondary central nervous system (CNS) lymphoma at the time of recruitment or history of CNS lymphoma
  • Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
  • History of other that could affect compliance with the protocol or interpretation of results
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection (as evaluated by the investigator) within 4 weeks prior to first study treatment
  • Suspected or latent tuberculosis
  • Positive test results for chronic virus (HBV) infection
  • Positive test results for virus (HCV) antibody
  • Known -seropositive status
  • Known or suspected chronic active Epstein-Barr virus infection
  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
  • History of progressive multifocal leukoencephalopathy
  • Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better (with the exception of alopecia and anorexia)
  • Administration of a live, attenuated vaccine within 4 weeks prior to the first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
  • Prior solid organ transplantation
  • Prior allogenic stem cell transplant
  • Active disease requiring treatment
  • Prior treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 4 weeks prior to the first dose of study treatment
  • therapy within 2 weeks prior to first dose of study treatment, with exceptions defined by the study protocol
  • Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis
  • history of liver disease, including cirrhosis
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Arm A: Glofit-GemOx

    Participants will receive up to 8 cycles of Glofit-GemOx (glofitamab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles, followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab.

    Drug: Glofitamab · Drug: Gemcitabine · Drug: Oxaliplatin · Drug: Obinutuzumab · Drug: Tocilizumab

  • Experimental
    Arm B: Mosun-GemOx

    Participants will receive up to 8 cycles of Mosun-GemOx (mosunetuzumab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles.

    Drug: Gemcitabine · Drug: Oxaliplatin · Drug: Mosunetuzumab · Drug: Tocilizumab

Interventions

  • Participants will receive intravenous (IV) glofitamab in combination with gemcitabine and oxaliplatin for up to 8 cycles, followed by up to 4 cycles of glofitamab monotherapy.

    Also known as: RO7082859

  • Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.

  • Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.

  • Participants will receive IV mosunetuzumab in combination with gemcitabine and oxaliplatin for up to 8 cycles.

    Also known as: RO7030816

  • Participants will receive a single dose of IV obinutuzumab 7 days prior to the first administration of glofitamab.

    Also known as: RO5072759

  • Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).

    Also known as: RO4877533

06

What researchers measure

Primary outcomes

  1. Number of Deaths Due to Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline - 90 days after last dose of study treatment

  2. Number of Treatment Discontinuations Due to AE

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline - 90 days after last dose of study treatment

  3. Proportion of Participants With Serious Adverse Events (SAEs)

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline - 90 days after last dose of study treatment

  4. Proportion of Participants With Cytokine Release Syndrome (CRS) by Grade of Severity

    Severity of CRS was determined according to the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Criteria, in which Grade 1 as fever (≥38.0°C) with or without other symptoms; Grade 2 as fever with hypotension not requiring vasopressors and/or hypoxia requiring the use of oxygen (low-flow); and Grade 3 as fever with hypotension requiring one vasopressor with or without vasopressin and/or hypoxia requiring the use of oxygen (high-flow).

    Time frame: Baseline - 90 days after last dose of study treatment

Secondary outcomes

  1. Tolerability of Study Treatment as Measured by Dose Interruptions, Dose Reductions, and Treatment Discontinuation Due to AEs

    Time frame: Up to approximately 16 months

  2. Complete Response (CR) Based on PET/CT as Determined by the Investigator According to the 2014 Lugano Response Criteria

    Per the 2014 Lugano Response Criteria for malignant lymphoma a CR = complete metabolic response with a score of 1, 2, or 3 on a 5-point scale (5PS), with higher scores indicating more extensive disease.

    Time frame: Up to approximately 16 months

  3. Objective Response Rate (ORR), Defined as the Proportion of Participants With a Best Overall Response of Partial Response (PR) or CR, as Determined by the Investigator According to the 2014 Lugano Response Criteria

    Per the 2014 Lugano Response Criteria for malignant lymphoma a CR = complete metabolic response with a score of 1, 2, or 3 on a 5-point scale (5PS), while a PR = partial metabolic response with a score of 4 or 5 on 5PS with higher scores indicating more extensive disease.

    Time frame: Up to approximately 16 months

  4. Maximum Serum Concentration (Cmax) of Glofitamab

    Time frame: Cycle 1 Day 8 and Cycle 2 Day 1

07

Results

Posted Mar 25, 2024

Participant flow

Participant flow — Overall Study
MilestoneArm A: Glofit-GemOxArm B: Mosun-GemOx
Started176
Completed53
Not completed123
Withdrew: Death123

Outcome measures

PrimaryNumber of Deaths Due to Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline - 90 days after last dose of study treatment
Reported as:
Number · Participants
Number of Deaths Due to Adverse Events (AEs)
ParticipantsArm A: Glofit-GemOxArm B: Mosun-GemOx
Number of Deaths Due to Adverse Events (AEs)10
SecondaryTolerability of Study Treatment as Measured by Dose Interruptions, Dose Reductions, and Treatment Discontinuation Due to AEs
Time frame:
Up to approximately 16 months
Reported as:
Number · percentage of participants
Tolerability of Study Treatment as Measured by Dose Interruptions, Dose Reductions, and Treatment Discontinuation Due to AEs
percentage of participantsArm A: Glofit-GemOxArm B: Mosun-GemOx
AEs leading to treatment discontinuation5.916.7
AEs leading to dose modification or interruption29.450.0
SecondaryComplete Response (CR) Based on PET/CT as Determined by the Investigator According to the 2014 Lugano Response Criteria

Per the 2014 Lugano Response Criteria for malignant lymphoma a CR = complete metabolic response with a score of 1, 2, or 3 on a 5-point scale (5PS), with higher scores indicating more extensive disease.

Time frame:
Up to approximately 16 months
Reported as:
Number · percentage
Complete Response (CR) Based on PET/CT as Determined by the Investigator According to the 2014 Lugano Response Criteria
percentageArm A: Glofit-GemOxArm B: Mosun-GemOx
Complete Response (CR) Based on PET/CT as Determined by the Investigator According to the 2014 Lugano Response Criteria23.5 (6.81 to 49.90)50.0 (11.81 to 88.19)
SecondaryObjective Response Rate (ORR), Defined as the Proportion of Participants With a Best Overall Response of Partial Response (PR) or CR, as Determined by the Investigator According to the 2014 Lugano Response Criteria

Per the 2014 Lugano Response Criteria for malignant lymphoma a CR = complete metabolic response with a score of 1, 2, or 3 on a 5-point scale (5PS), while a PR = partial metabolic response with a score of 4 or 5 on 5PS with higher scores indicating more extensive disease.

Time frame:
Up to approximately 16 months
Reported as:
Number · Proportion expressed as percentage
Objective Response Rate (ORR), Defined as the Proportion of Participants With a Best Overall Response of Partial Response (PR) or CR, as Determined by the Investigator According to the 2014 Lugano Response Criteria
Proportion expressed as percentageArm A: Glofit-GemOxArm B: Mosun-GemOx
Objective Response Rate (ORR), Defined as the Proportion of Participants With a Best Overall Response of Partial Response (PR) or CR, as Determined by the Investigator According to the 2014 Lugano Response Criteria35.350.0
SecondaryMaximum Serum Concentration (Cmax) of Glofitamab
Time frame:
Cycle 1 Day 8 and Cycle 2 Day 1
Reported as:
Median · ug/mL
Maximum Serum Concentration (Cmax) of Glofitamab
ug/mLArm A: Glofit-GemOx
Pre-infusion Cycle 1 Day 80 (0 to 0)
Within 30 mins post infusion Cycle 1 Day 80.6 (0.3 to 1.7)
12 hours post infusion Cycle 1 Day 80.6 (0.1 to 0.9)
24 hours post infusion Cycle 1 Day 80.5 (0.1 to 0.8)
48 hours post infusion Cycle 1 Day 80.3 (0 to 0.4)
Pre-infusion Cycle 2 Day 10.8 (0.1 to 1.3)
Within 30 minutes post infusion Cycle 2 Day 19 (6.8 to 17.7)
6 hours post infusion Cycle 2 Day 17.8 (5.5 to 13.1)
20 hours post infusion Cycle 2 Day 16.5 (4.4 to 11.2)
44 hours post infusion Cycle 2 Day 13.8 (3.2 to 4.3)
PrimaryNumber of Treatment Discontinuations Due to AE

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline - 90 days after last dose of study treatment
Reported as:
Number · Participants
Number of Treatment Discontinuations Due to AE
ParticipantsArm A: Glofit-GemOxArm B: Mosun-GemOx
Number of Treatment Discontinuations Due to AE11
PrimaryProportion of Participants With Serious Adverse Events (SAEs)

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline - 90 days after last dose of study treatment
Reported as:
Number · Proportion expressed as percentage
Proportion of Participants With Serious Adverse Events (SAEs)
Proportion expressed as percentageArm A: Glofit-GemOxArm B: Mosun-GemOx
Proportion of Participants With Serious Adverse Events (SAEs)70.666.7
PrimaryProportion of Participants With Cytokine Release Syndrome (CRS) by Grade of Severity

Severity of CRS was determined according to the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Criteria, in which Grade 1 as fever (≥38.0°C) with or without other symptoms; Grade 2 as fever with hypotension not requiring vasopressors and/or hypoxia requiring the use of oxygen (low-flow); and Grade 3 as fever with hypotension requiring one vasopressor with or without vasopressin and/or hypoxia requiring the use of oxygen (high-flow).

Time frame:
Baseline - 90 days after last dose of study treatment
Reported as:
Number · Proportion expressed as percentage
Proportion of Participants With Cytokine Release Syndrome (CRS) by Grade of Severity
Proportion expressed as percentageArm A: Glofit-GemOxArm B: Mosun-GemOx
Grade 129.416.7
Grade 211.80
Grade 35.90

Adverse events

Collected over Baseline - 90 days after the final dose of study treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Glofit-GemOx1/17 (5.9%)12/17 (70.6%)17/17 (100%)
Arm B: Mosun-GemOx0/6 (0%)4/6 (66.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventArm A: Glofit-GemOxArm B: Mosun-GemOx
PyrexiaGeneral disorders6/171/6
FallInjury, poisoning and procedural complications0/172/6
SepsisInfections and infestations3/170/6
DiarrhoeaGastrointestinal disorders1/171/6
AstheniaGeneral disorders0/171/6
Hepatic cirrhosisHepatobiliary disorders0/171/6
Cytokine release syndromeImmune system disorders2/171/6
Urinary tract infectionInfections and infestations1/171/6
Immune effector cell-associated neurotoxicity syndromeNervous system disorders0/171/6
NeutropeniaBlood and lymphatic system disorders2/170/6
Most frequent other events
Showing 10 of 104
Most frequent other events
EventArm A: Glofit-GemOxArm B: Mosun-GemOx
DiarrhoeaGastrointestinal disorders6/175/6
NauseaGastrointestinal disorders4/174/6
FatigueGeneral disorders4/174/6
HypomagnesaemiaMetabolism and nutrition disorders6/174/6
HypophosphataemiaMetabolism and nutrition disorders4/174/6
AnaemiaBlood and lymphatic system disorders6/173/6
ConstipationGastrointestinal disorders4/173/6
Urinary tract infectionInfections and infestations1/173/6
Peripheral sensory neuropathyNervous system disorders3/173/6
Cytokine release syndromeImmune system disorders7/170/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: Glofit-GemOxArm B: Mosun-GemOxTotal
Mean61.1 ± 8.769.3 ± 18.363.3 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Glofit-GemOxArm B: Mosun-GemOxTotal
Female426
Male13417
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Glofit-GemOxArm B: Mosun-GemOxTotal
Hispanic or Latino000
Not Hispanic or Latino17623
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Glofit-GemOxArm B: Mosun-GemOxTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American000
White15520
More than one race000
Unknown or Not Reported000
08

Study locations

3 sites
  • Prince of Wales Hospital; Haematology
    Randwick, New South Wales 2031, Australia
  • Monash Health Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Oct 2021, 16 months.

Results were first posted in Mar 2024, 2 years 4 months after primary completion.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 16 months is below that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2020
First posted
Mar 18, 2020
StartActual
Jun 4, 2020
Primary completionActual
Oct 26, 2021
CompletionActual
Oct 26, 2021
Results first posted
Mar 25, 2024
Last update
Mar 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04313608
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 18, 2020
Start date
Jun 4, 2020
Primary completion
Oct 26, 2021
Completion
Oct 26, 2021
Results posted
Mar 25, 2024
Last update
Mar 25, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glofitamab · Mosunetuzumab

Start the discussion